XML 20 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash Flows from Operating Activities    
Net income (loss) $ 499,568 $ (796,161)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Amortization of debt issuance cost 223,191 215,302
Depreciation and amortization 1,493,285 1,170,778
Stock based compensation expense 1,458,850 2,200,160
Stock issued for services 50,000
Settlement expense 56,250
Loss on extinguishment of debt 657,180
Amortization of debt discount 1,620,151
Impairment of goodwill and intangible assets 2,176,910
Foreign currency transaction loss (gain) 120,549 (13,503)
Change in the fair value of derivative liability (1,380,600)
Remeasurement (gain) loss on translation of foreign subsidiary (50,825) 54,345
Non cash implied interest 73,763 114,213
Write-off of inventory 180,122
Loss on sale of assets 2,877
Changes in operating assets and liabilities:    
Accounts receivable (2,085,778) 1,734,466
Inventory (1,449,425) (547,295)
Prepaid expense and other current assets 205,351 (1,051,168)
Deferred revenue (32,942) 36,000
Accounts payable and accrued liabilities (1,289,534) (438,530)
Net cash (used in) provided by operating activities (831,070) 6,038,620
Cash Flows from Investing Activities    
Payments for acquisition of fixed assets (153,021) (302,227)
Restricted cash (39,071) 507,084
Cash received from sale of assets 6,199
Payments for brand development fees (1,761,935)
Payment of earn out liability (2,551,500)
Net cash used in investing activities (1,947,828) (2,346,643)
Cash Flows from Financing Activities    
Proceeds from notes payable 10,000,000
Repayment of notes payable (7,456,250) (4,831,250)
Payment of debt issuance cost (452,869)
Proceeds from sale of common stock 220,000
Net cash provided by (used in) financing activities 2,310,881 (4,831,250)
Effect of exchange rate on cash and cash equivalents (94,011) 16,022
Net decrease in cash and cash equivalents (562,028) (1,123,251)
Cash and Cash Equivalents, beginning of year 2,517,642 3,640,893
Cash and Cash Equivalents, end of year 1,955,614 2,517,642
Supplemental Disclosure of Cash Flow Information:    
Interest 842,248 1,488,123
Income taxes 1,194,233 864,864
Supplemental Disclosure of Non-cash Investing and Financing Activities:    
Reallocation of goodwill related to acquisition of Factor Nutrition to intellectual property 450,000
Reallocation of goodwill related to acquisition of Breakthrough Products, Inc. to intellectual property 150,000
Reallocation of non-compete agreement related to acquisition of Breakthrough Products, Inc. to goodwill 50,000
Adjusting the value of goodwill for the value of shares issued related to acquisition of Breakthrough Products, Inc. 1,170,000
Reallocation of blogger database and intellectual property related to acquisition of Nomadchoice Pty Ltd. to customer database 215,000
Common stock to be issued now issued 56,250 68,000
Cancellation of common stock 125,000
Common stock issued for the acquisition of assets of Per-fekt 241,396
Common stock issued in conjunction with cancellation of warrants and options issued concurrent with debt 1,456,492
Adjustment of accounts receivable and payables created during acquisition of Neuragen 24,592
Inventory written-off and adjusted against accounts receivable and payables created during acquisition of Neuragen $ 48,949